Skip to main content

Day: May 1, 2020

Fidelity D & D Bancorp, Inc. Announces Completion of the Acquisition of MNB Corporation

DUNMORE, Pa., May 01, 2020 (GLOBE NEWSWIRE) — Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) (“Fidelity”), the parent bank holding company of The Fidelity Deposit and Discount Bank (“Fidelity Bank”), a Pennsylvania state-chartered, FDIC-insured community bank and trust company headquartered in Dunmore, PA, announced the completion of the acquisition of  MNB Corporation (OTCPink: MNBC) (“MNB”) and its wholly-owned subsidiary, Merchants Bank of Bangor effective May 1, 2020.Under the terms of the Reorganization Agreement, MNB stockholders received 1.039 shares of Fidelity common stock for each share of MNB common stock that they owned as of the effective date. As a result, Fidelity issued approximately 1,177,055 shares of its common stock and cash in exchange for fractional shares based upon $43.767 determined market share price...

Continue reading

CHF Solutions Ships Aquadex Product to COVID-19 Specialty Center in Minnesota

EDEN PRAIRIE, Minn., May 01, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has shipped Aquadex product to a specialty care center designated for the most severe COVID-19 patients in Minnesota.“We continue to receive positive feedback from physicians and medical staff who are using Aquadex therapy to treat patients affected with COVID-19 throughout the country,” said John Erb, CEO of CHF Solutions. “With these first shipments within Minneapolis-St. Paul, we are pleased that the Aquadex therapy is being used to help patients in our own community.”Several hospitals across the country have included a simplified ultrafiltration system, such as Aquadex therapy, into their treatment protocol for fluid management...

Continue reading

Conifex To Extend COVID-19 Curtailment

VANCOUVER, British Columbia, May 01, 2020 (GLOBE NEWSWIRE) — Conifex Timber Inc. (TSX: CFF) announced today that, in response to continued weakened global demand for forest products amid sustained uncertainty from the economic impact of the COVID-19 pandemic, it is extending its temporary production curtailment at its Mackenzie, British Columbia sawmill for four weeks to June 1, 2020.  The curtailment is not expected to have any adverse consequence on bioenergy operations.Conifex will continue to closely monitor the evolving market conditions, customer demand and the global COVID-19 response while prioritizing employee health and safety considerations.For further information, please contact:About Conifex Timber Inc.Conifex and its subsidiaries’ primary business currently includes timber harvesting, reforestation, forest management,...

Continue reading

Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx™ and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx™

Abstracts selected for oral presentation at the American Thoracic Society 2020 International Conference and published in American Journal of Respiratory and Clinical Care MedicineNew data on the DetermaRx™ treatment stratification test for non-small cell lung cancer demonstrates potential clinical utility and benefit to patients and payers through reduced post-surgery follow up of lung cancer patientsIRVINE, Calif., May 01, 2020 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the publication of two abstracts in the American Journal of Respiratory and Clinical Care Medicine, one detailing new data on DetermaRx™, and the other highlighting the IRENE clinical study...

Continue reading

Primoris Services Corporation Announces Utility Award Valued Over $22 Million

DALLAS, May 01, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced a new utility award valued over $22 million.  The contract was secured by ARB Underground, part of the Utilities & Distribution segment. The award is for the inspection of electrical transmission and distribution poles and towers at over 225,000 locations across Northern California.Work is scheduled to commence in the second quarter of 2020, and completion is expected in the fourth quarter of 2020.ABOUT PRIMORISFounded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating mainly in the United States and Canada. Primoris provides a wide range of specialty construction services, fabrication, maintenance,...

Continue reading

MSG Networks Inc. Reports Fiscal 2020 Third Quarter Results

Fiscal 2020 third quarter revenues of $185.0 millionFiscal 2020 third quarter operating income of $73.7 millionFiscal 2020 third quarter adjusted operating income of $79.1 millionNEW YORK, May 01, 2020 (GLOBE NEWSWIRE) — MSG Networks Inc. (NYSE: MSGN) today reported financial results for the fiscal 2020 third quarter ended March 31, 2020.For the fiscal 2020 third quarter, MSG Networks Inc. generated revenues of $185.0 million, a decrease of 5% as compared with the prior year period.  In addition, the Company generated operating income of $73.7 million, a decrease of 11%; adjusted operating income of $79.1 million, a decrease of 11%; and net income of $46.3 million, a decrease of 15%; all as compared with the prior year period.(1)President and CEO Andrea Greenberg said, “During these unprecedented times, we are reminded of...

Continue reading

Bel Reports First Quarter 2020 Results

JERSEY CITY, N.J., May 01, 2020 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a designer, manufacturer and provider of products that power, protect and connect electronic circuits, today announced preliminary financial results for the first quarter of 2020.First Quarter 2020 HighlightsNet sales of $104.0 million, down 17.1% from Q1-19Gross profit margin of 24.2%, down from 24.5% in Q1-19Net loss of $3.8 million, as compared with net earnings of $1.1 million in Q1-19CUI acquisition in December 2019 contributed $8.2 million to Q1-20 sales at a gross profit margin of 36.8%Backlog of $191.2 million at March 31, 2020, up 19% from year-endCash flow provided by operating activities of $8.1 millionNon-GAAP financial measures, such as Non-GAAP net earnings, Non-GAAP EPS, EBITDA and Adjusted EBITDA, exclude the impact of acquisition-related costs...

Continue reading

Houston Wire & Cable Company Announces First Quarter 2020 Earnings Conference Call

HOUSTON, May 01, 2020 (GLOBE NEWSWIRE) — Houston Wire & Cable Company (Nasdaq:HWCC) will hold a conference call on Friday, May 8, 2020, at 10:00 a.m. C.T., to discuss First Quarter 2020 results. Hosting the call will be James Pokluda, President & Chief Executive Officer and Chris Micklas, Vice President & Chief Financial Officer.Date: Friday, May 8, 2020Time: 10:00 a.m. C.T.A live audio web cast of the call will be available at http://ir.houwire.com.Live call dial-in numbers are as follow:Toll-Free: (800) 936-7954International: (720) 545-0048Conference ID #2499159Approximately two hours after the completion of the live call, a telephone replay will be available until May 15, 2020. Interested parties should use the following replay phone numbers:Replay, Toll-Free: 855-859-2056Replay, Toll: 404-537-3406Conference ID...

Continue reading

TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase 3 ULTIMATE MS programAnnualized Relapse Rate of 0.07 observed at week 48NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the multicenter Phase 2 trial evaluating ublituximab, the Company’s investigational, glycoengineered, anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), in the Multiple Sclerosis Journal.Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are extremely pleased to see the ublituximab Phase 2 results published in Multiple Sclerosis Journal. Anti-CD20 therapy has quickly become a very important...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.